Research Article
No access
Published Online: 5 July 2004

Combining Dosimetry for Targeted Radionuclide and External Beam Therapies Using the Biologically Effective Dose

Publication: Cancer Biotherapy and Radiopharmaceuticals
Volume 18, Issue Number 1


It is not uncommon for a patient to receive both external beam and targeted radionuclide therapy during the course of a cancer treatment. The total dose received by the tumor and by normal tissues will therefore be subject to the contributions of both treatment modalities. However, the two treatments are generally applied independently of one another, with little attention paid to the combined effect. With the availability of patient-specific three-dimensional dosimetry for radionuclide therapies, it is pertinent now to consider the combined effect of the two treatments, and to investigate how dosimetry for this situation may be carried out.
Methodology has been developed to allow a combination of dose information from the two types of therapy. The biologically effective dose (BED) has been employed to address the issue of inequivalence of biological effect of the two therapies. Dose distributions have been represented as distributions of BED, and the net effect resulting from the combination of these two therapies demonstrated through a combination of BED maps. Examples are presented of cases in which this analysis of a combined therapy provides a more favorable treatment than either therapy alone. For one patient the ratio of the mean spinal cord dose to the mean CTV dose was calculated for both an external beam therapy alone and for a combined therapy and was found to be 0.40 and 0.16, respectively.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors


Published In

cover image Cancer Biotherapy and Radiopharmaceuticals
Cancer Biotherapy and Radiopharmaceuticals
Volume 18Issue Number 1February 2003
Pages: 89 - 97
PubMed: 12667312


Published online: 5 July 2004
Published in print: February 2003


Request permissions for this article.




R. K. Bodey
Institute of Cancer Research, Sutton, Surrey, United Kingdom
G. D. Flux
Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom
P. M. Evans
Institute of Cancer Research, Sutton, Surrey, United Kingdom

Metrics & Citations



Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options


View PDF/ePub







Copy the content Link

Share on social media

Back to Top